Board Appointments

Closed Loop Medicine

Non-Executive Director Closed Loop Medicine is a TechBio company developing combination prescription drug plus software products, with the aim of redefining precision medicine. The Company’s proprietary technology platform facilitates personalised drug dosing optimisation, through integration of drugs and software with patient-led digital experiences and closed loop models of care. This approach has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Founded at the Babraham Institute in Cambridge, UK in 2017, and now based in London, UK, Closed Loop Medicine (CLM) has to date raised over £22 million GBP ($30 million USD) in [...]

By |28 July 2022|Categories: |Tags: |0 Comments

Owlstone Medical

Non-Executive Director Owlstone Medical Ltd is an award-winning and innovative growth stage global diagnostics organisation pioneering the development of a breathalyzer for applications in early disease detection and precision medicine. Founded in 2014, as a spin out of the successful Owlstone Inc. business, Owlstone Medical has a mission to save over 100,000 lives through the deployment of its clinical stage Breath Biopsy® platform for early disease detection and precision medicine. In 2021, following impressive growth, with over 170 employees and having raised almost $100m in investment, Owlstone Medical’s Board of Directors determined a strategic business need to appoint an internationally [...]

By |24 January 2022|Categories: |Tags: |0 Comments

Futura Medical

Non-Executive Directors Futura Medical PLC (“Futura” or the “Company”) is an AIM listed pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain. In 2021, Futura received EU regulatory approval for its breakthrough, fast acting topical gel formulation for the treatment of erectile dysfunction (“ED”) and is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction known as MED3000 (Eroxon™). In addition, the remaining clinical study that the Company believes is required in order to submit MED3000 for US [...]

By |13 January 2022|Categories: |Tags: |0 Comments


Non-Executive Finance Trustee LifeArc is a leading independent medical research charity that rebranded since its formation as the MRC-T over 25 years ago. LifeArc’s expertise has helped bring a number of new innovations to market including major commercialised antibody treatments such as Keytruda® (pembrolizumab). As an independent charity, LifeArc is guided and governed by a Board of Trustees comprised of leading figures from the Pharmaceutical, Biotech, Charitable and Investment sector. As part of a strategic relationship, PIR International partnered with LifeArc to appoint a new Non-Executive Finance Trustee to its board. As a result of a thorough search exercise, drawing [...]

By |01 September 2020|Categories: |Tags: |0 Comments
Go to Top